Duration: February 2012-2016 (5-year project)
Funding programme: Innovative Medicines Initiative (IMI), a public private partnership between the European Commission and EFPIA
The Patients’ Academy will:
To improve the availability of both patient-centric information as well as educated patient experts, EUPATI will develop scientifically reliable, objective, comprehensive information on therapeutic innovation by:
The consortium comprises of 30 leading pan-European patient organisations, academic and not-for profit organisations as well as EFPIA member companies. It features excellence across disease areas in state-of-the art, high quality, objective education to patients about therapeutic innovation. It will foster collaboration between patient organisations, academic institutions, regulatory bodies, ethics committees and the industry.
A Regulatory Advisory Panel led by regulatory authorities as well as a Project Advisory Board composed of high level experts with long standing credibility in patient involvement and pharmaceutical R&D will ensure objectivity, transparency and independence of EUPATI’s educational content, adhering to the highest quality standards on information to patients.
Impact on patient community
Well informed patients and carers have a key role to play in the implementation of patient-centred clinical research strategies, approval processes, access to treatments and treatment optimization. With appropriate training, patient advocates can become accepted partners in scientific, ethical and regulatory committees which can accelerate and improve clinical trials, drug development and access strategies. Furthermore, educating the public can reduce scrutiny against clinical research and therapeutic innovation.